Abstract
We have demonstrated previously that protein kinase Cα(PKCα) plays a key role in regulating phospholipase D (PLD) activation by nucleotides and the phorbol ester phorbol-12-myristate-13-acetate in Madin-Darby canine kidney (MDCK-D1) cells. In the current work, we investigated PLD activation in MDCK-D1 cells triggered by the adrenergic receptor agonist epinephrine and its mechanism of activation. Epinephrine, acting through the α1-adrenergic receptor subtype, promoted transient translocation of PKCα and more prolonged translocation of PKCε to the membrane fraction, indicating activation of these two isoforms. In addition, epinephrine promoted activation of PLD, as shown by a sustained accumulation of phosphatidylethanol. All of these events were blocked by pretreatment of cells with the α1-adrenergic antagonist prazosin. D609, an inhibitor of phosphatidylcholine hydrolysis, blocked translocation of PKCα and PKCε but did not inhibit PLD activation. Unlike results with PMA, or with the P2purinergic receptor agonist ATP, epinephrine-stimulated PLD activity was not inhibited in MDCK-D1 cells in which PKCαexpression is attenuated by an antisense cDNA construct or in cells in which PKC activity was inhibited by 1 μm GF 109203X. However, PLD activation by epinephrine was abolished by concomitant incubation of cells with the calcium chelator EGTA. These data, together with previous results, are consistent with the hypothesis that in MDCK-D1 cells, epinephrine acting on α1-adrenergic receptors, promotes a rapid increase in cytosolic Ca2+ that promotes activation of PLD through an as-yet poorly defined mechanism. The data demonstrate that different types of G protein-linked receptors that activate PLD can mediate this activation in either a PKC activation-dependent or -independent manner within a single cell type.
PLD activity is found in a variety of cells and tissues and seems to play a key role in cellular signaling (Liscovitch and Chalifa, 1994). PLD catalyzes the hydrolysis of the terminal phosphodiester bond of phospholipids, yielding phosphatidic acid and a free polar headgroup. Phosphatidic acid may act directly as a signal molecule, or can be metabolized to form diacylglycerol by phosphatidate phosphohydrolase (Martin et al., 1994). The latter can function as an activator of PKC, a key enzyme in cellular signaling (Nishizuka, 1995)
Substantial evidence indicates that PKC activation can lead to PLD activation in response to receptor agonists (Liscovitch and Chalifa, 1994). We have demonstrated the importance of PKC, in particular the α isoform, in regulating PLD activation in MDCK-D1 cells responding to nucleotides or phorbol ester (Balboa et al., 1994). Using different approaches, other researchers have also highlighted the importance of PKCα in regulating cellular PLD activity (Eldar et al., 1993; Conricode et al., 1994; Lopez et al., 1995).
In the current study, we examined the activation of PLD in MDCK-D1 cells stimulated by another stimulus, the adrenergic receptor agonist epinephrine. Norepinephrine and epinephrine, acting via α1-adrenergic receptors, have been reported to stimulate PLD in a variety of tissues, including cerebral cortex, parotid gland, aorta, tail artery, hepatocytes, and cardiac myocytes (Gu et al., 1992; Llahi and Fain, 1992; Pittner and Fain, 1992; Jones et al., 1993; Guillemain and Rossignol, 1994; Yeet al., 1994; LaBelle et al., 1996). Although the mechanism involved in this activation is poorly understood, in several of those systems, a role for PKC has been inferred. Because of the previously demonstrated role for PKCα in PLD activation in MDCK-D1 cells (Balboa et al., 1994), we hypothesized that activation of PKCα would be required for activation of PLD by epinephrine in MDCK-D1 cells. However, we now report that, although epinephrine activates PKCα, this activation was not associated with an activation of PLD. We also find that epinephrine activates PKCε, although this isoenzyme also does not seem to be involved in PLD activation. On the other hand, we find that Ca2+ is very important for PEt production by epinephrine. Therefore, the current study, along with our previous data (Slivka and Insel, 1987; Slivka et al., 1988), demonstrates that different mechanisms can be utilized by different types of G protein-linked receptors to activate PLD in a single cell type.
Experimental Procedures
Materials.
[3H]Palmitic acid (specific activity, 54 Ci/mmol) was purchased from New England Nuclear (Boston, MA). PMA and ATP were from Sigma (St. Louis, MO). Phosphatidylethanol (PEt) and D609 were obtained from Biomol (Plymouth Meeting, PA). PKC antibodies against α and β isoforms were from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against PKC isoforms δ, ε, and ζ, and the PKC inhibitor GF 109203X were purchased from Calbiochem (San Diego, CA). G-60 thin layer chromatography plates were purchased from Whatman (Clifton, NJ). The organic solvents were from Fisher (Pittsburgh, PA).
PLD activation.
MDCK-D1 were labeled the day before to 80% confluency with [3H]palmitic acid (2.5 μCi/ml). After removal of labeling medium, cultures were rinsed twice with phosphate-buffered saline (10 mm phosphate buffer, 2.7 mm KCl, 137 mm NaCl, pH 7.6) and equilibrated with serum-free medium (Dulbecco’s modified Eagle’s medium) containing 1 mg/ml bovine serum albumin at 37° for 3 hr. Cells were incubated with specified concentration of epinephrine for the indicated times (see figure legends) in the presence of 1% ethanol. After stopping the reactions, the lipids were extracted and PEt was separated by thin layer chromatography as described previously (Balboa et al., 1994).
Separation of cytosolic and membrane fractions.
Cells were washed twice with Dulbecco’s modified Eagle’s medium, 20 mm HEPES, 0.05% bovine serum albumin and then treated with 50 μm epinephrine, 300 μm ATP, or 80 nm PMA for the indicated time (see figure legends) at 37°. The cells were washed twice with 4 ml of ice-cold 20 mm Tris, 2 mm EDTA, 10 mm EGTA, 1 mm phenylmethylsulfonyl fluoride, 20 μmleupeptin, 20 μm aprotinin, 0.1% 2-mercaptoethanol, pH 7.5, and scraped into 4 ml of that buffer. The cell suspension was homogenized with 25 strokes of a Dounce homogenizer. The homogenates were centrifuged at 500 × g for 5 min (4°) to separate nuclei, and the remaining supernatant was centrifuged at 35,000 × g for 35 min to separate soluble and particulate fractions (Slivka et al., 1988). After protein quantification, Western blot analyses were performed on these two fractions.
Western blot analyses.
Samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on a 10% gel (75 μg of protein/lane) and transferred to Immobilon-P (Millipore, Bedford, MA). Nonspecific binding was blocked by incubating the membranes with 5% nonfat milk in phosphate-buffered saline for 60 min. Membranes were incubated with specific antisera against PKCα or PKCε isoform for 30 min, and then treated with horseradish peroxidase-conjugated protein A (Amersham, Arlington Heights, IL). Bands were detected by enhanced chemiluminescence (Amersham).
Results
PLD activation has been shown previously to be activated after stimulation of MDCK-D1 cells by P2-purinergic receptors and phorbol esters (Balboa et al., 1994). In the current study, we investigated whether α-adrenergic receptors on MDCK-D1 cells are also coupled to PLD activation. To this end, [3H]palmitic acid-labeled cells were used and PLD activation was monitored by taking advantage of the unique ability of PLD to catalyze a transphosphatidylation reaction in the presence of ethanol.
Incubation of [3H]palmitate-labeled MDCK-D1 cells with the adrenergic receptor agonist epinephrine in the presence of 1% ethanol resulted in a time-dependent generation of [3H]PEt (Fig.1A). PEt production increased linearly up to 5 min, and then ceased rapidly. The kinetics of epinephrine-induced PEt accumulation are similar to those observed previously when P2-purinergic receptor agonists were used to elicit PLD activation (Balboa et al., 1994) and suggest a rapid desensitization of PLD activity by both types of agonists.
PEt accumulation in response to epinephrine was also concentration-dependent, with an EC50 value of ∼0.5 μm and maximal response at concentrations above 1 μm (Fig. 1B). These concentrations are similar to those observed previously for epinephrine-promoted phosphoinositide hydrolysis, arachidonic acid release, and prostaglandin E2 formation in MDCK-D1 cells (Slivka and Insel, 1987; Weiss et al., 1989; Howard and Insel, 1990; Weiss and Insel, 1991). To determine which adrenergic receptor subtype was linked to PLD activation, we studied the effects of prazosin, an α-adrenergic antagonist, and propranolol, a β-adrenergic antagonist. Complete inhibition of epinephrine-induced PEt production was found in the presence of prazosin, but not propranolol (Fig.1 C). Thus, PLD activation in response to epinephrine is caused by α1-adrenergic receptor occupancy.
We know that stimulation of α1-adrenergic receptors increases phospholipase C-mediated phosphoinositide hydrolysis in different cell types, including MDCK-D1 cells (Slivka and Insel, 1987; Howard and Insel, 1990; Weiss and Insel, 1991). To study the relationship, if any, between phosphoinositide hydrolysis and PLD activation in response to epinephrine, we used the aminoglycoside antibiotic neomycin. Neomycin inhibits phosphoinositide-specific phospholipase C activation (Lipsky and Leitman, 1982; Schwertz et al., 1984) and has been used previously in our laboratory to ascertain the relationship between phosphoinositide hydrolysis and PLD activation in response to purinergic stimulation and phosphoinositide hydrolysis and arachidonic acid release in response to other agonists (Slivka and Insel, 1987; Slivka and Insel, 1988). At concentrations found previously to inhibit phosphoinositide-specific phospholipase C in MDCK-D1 cells (Balboa et al., 1994), we failed to detect a significant decrease in epinephrine-stimulated PLD activity by neomycin (Fig. 2A).
We have shown previously that epinephrine increases Ca2+ accumulation in MDCK-D1 cells, partly from entry of Ca2+ from the extracellular medium (Weiss and Insel, 1991). Therefore, we assessed a role for Ca2+ in PLD activation by employing the Ca2+ chelator EGTA. Addition of 2 mmEGTA to the incubation medium for 5 min before epinephrine stimulation, markedly inhibited PLD activation (Fig. 2 B). These data, which are similar to those observed for P2-purinergic receptor-activated MDCK-D1 cells (Balboa et al. 1994), suggest that Ca2+ is involved in PLD activation by α1-adrenergic receptor stimulation (Huanget al., 1992; Balboa et al., 1994). Ca2+ is also necessary for observing PLD activity in homogenates from MDCK-D1 cells (Balboa et al., 1995;Balboa and Insel, 1995).
Our previous studies (Balboa et al., 1994; Balboa et al., 1995; Balboa and Insel, 1995) have demonstrated an essential role for PKCα (and Ca2+) in P2-purinergic stimulation of PLD in MDCK-D1 cells. To investigate whether activation of PKCα or other PKC isoforms plays a similar regulatory role in α1-adrenergic stimulation of MDCK-D1 cells, we analyzed the kinetics of translocation of the PKC isoforms present in these cells (α, β, δ, ε, and ζ) from the cytosol to membrane fractions in response to epinephrine. The data in Fig. 3 show that addition of epinephrine to the cells resulted in activation of PKCα, leading to its translocation to the membrane fraction. Translocation of PKCα was very transient, reaching a maximum 5 sec after addition of epinephrine and disappearing from the membrane after 30 sec of stimulation. (Fig. 3, A and B).
In comparison with results obtained with epinephrine, the pattern of PKCα translocation in response to treatment of MDCK-D1 cells with the P2-purinergic agonist ATP was more delayed and sustained (Fig. 3). Maximal translocation of PKCα to the membrane fraction was found between 30 and 60 sec after addition of ATP, with a slow subsequent decay in translocated enzyme. The behavior of PKCα in response to ATP showed a good correspondence with the kinetics of PEt accumulation induced by ATP in MDCK-D1 cells (see Fig. 3B in ), lending additional evidence in favor of the modulatory role that PKCα plays in PLD activation under these experimental conditions (Balboa et al., 1994).
PKCε was also translocated to the membrane fraction in response to epinephrine (Fig. 3, E and F), reaching a maximum at 30 sec and decreasing slowly thereafter. We could not detect translocation of PKC isoforms β, δ, or ζ after epinephrine stimulation (data not shown).
To determine whether translocation of PKCα and PKCε by epinephrine was caused by α1-adrenergic receptors, we performed experiments in the presence of prazosin. As shown in Fig.4, changes in PKCα and PKCε content in the membrane fraction were prevented by pretreatment with 5 μm prazosin, indicating the involvement of α1-adrenergic receptors.
The very transient nature of PKCα translocation in response to epinephrine makes it difficult to envision a role for PKCα activity in epinephrine-mediated activation of PLD. Accordingly, we found a complete dissociation of PKCα translocation and PLD activation by epinephrine using D609, a purported inhibitor of phospholipase C-mediated breakdown of phosphatidylcholine (Muller-Decker, 1989;Schütze et al., 1992). D609 blocked translocation of PKCα and PKCε to the membrane fraction in response to epinephrine (Fig.5A), but did not substantially inhibit epinephrine-induced PLD activation (Fig. 5B).
Further evidence for the lack of involvement of PKCα in PLD activation by epinephrine was obtained with the use of cells in which PKCαlevels were attenuated by means of an antisense technique (Godsonet al., 1993). Using these cells, we have previously demonstrated decreased PLD activation in response to PMA and ATP (Balboa et al., 1994); in contrast, however, the extent of epinephrine-induced activation of PLD in PKCαdepleted cells was similar to that found in wild-type cells (Fig.6).
We extended our data by using PKC inhibitors. As shown in Fig.7, 1 μm GF 109203X (a PKC inhibitor able to inhibit PKCα and PKCε isoforms) (Martiny-Baron et al., 1993), substantially blunted PEt production in MDCK-D1 cells stimulated by PMA and ATP. However, epinephrine-induced PEt accumulation was not affected by GF 109203X, suggesting a PKC activity independent mechanism of PLD activation.
Discussion
PKC activation constitutes one of the most widespread mechanisms for regulating PLD in eukaryotic cells (Liscovitch and Chalifa, 1994). PKC comprises a family of related enzymes that are differentially expressed in a variety of tissues and cell types (Nishizuka, 1995). At least 10 PKC isoforms have been described; recently, much effort has been directed at defining the role of PKC isoforms in the regulation of various biological processes, including activation of PLD. By reducing the levels of PKCα by an antisense method, we have demonstrated previously that PKCαregulates P2-purinergic activation of PLD in MDCK-D1 cells (Balboa et al., 1994). Data in this study have extended this observation by showing a good correspondence between the time-course of translocation of PKCα to membranes in response to ATP and the time-course of activation of PLD in response to this agonist. However, additional new data implicate a different mechanism for PLD activation in epinephrine-treated cells.
We have reorted previously that epinephrine increases cytosolic Ca2+ levels in MDCK-D1cells, a response that seems to be highly dependent on extracellular Ca2+ (Weiss and Insel, 1991). In this study, we observed that PLD activation by epinephrine is completely abolished by treatment of cells with 2 mm EGTA, suggesting an important role for Ca2+ in the response. Ca2+ ionophores increase PLD activity in many cellular systems (Billah et al., 1989; Gustavsson et al., 1994; Liscovitch and Chalifa, 1994), including MDCK-D1 cells (Balboa MA, unpublished observations, 1997), but the mechanism for this increase is uncertain. A highly regulated PLD (PLD1) was cloned byHammond et al. (1995). The sequence reveals no Ca2+-binding sites, making it difficult to explain a direct role for Ca2+ in PLD activation. However, it is possible that a Ca2+-regulated PLD isoform, perhaps present in MDCK-D1 cells (Huanget al., 1992), has not yet been cloned and sequenced.
Some investigators have implicated Ca2+mobilization in PKC activation, which could subsequently regulate PLD activity (Liscovitch and Chalifa, 1994). Nevertheless, other data have implicated a phosphorylation-independent PKC-mediated activation mechanism of PLD (Conricode et al., 1992; Singer et al., 1996). Such data included studies with PKC inhibitors and the fact that the PKCα regulatory domain, but not the active kinase domain, was an effective activator for PLD (Singeret al., 1996). In this scenario, Ca2+plays such an important role that, in the absence of Ca2+, PLD is not activated by PKCα, whereas the presence of Ca2+ allows stimulation by PKCα alone and synergy with low-molecular-weight G proteins, such as ADP-ribosylation factor (Singer et al., 1996). The precise mechanism by which Ca2+ promotes PLD activation by α1-adrenergic receptors in MDCK-D1 cells is uncertain and will require future study.
MDCK-D 1 cells express PKCα, -β,-ε, -δ and-ζ (Martiny-Baron et al., 1993; Balboa MA, unpublished observations, 1997). We have studied PKC translocation as an indication of PKC activation in epinephrine-treated MDCK-D1 cells. The results show that only PKCα and PKCε are translocated to the membrane fraction (Fig. 3). PKCα is very transiently recruited, and after 15 sec of stimulation, it disappears rapidly from the membrane fraction (Fig. 3). Movement of PKC isoforms off of the membrane to the cytosol fraction has been described before. For example, ceramide has been shown to induce the cytosolic localization of PKCδ and PKCε in several human leukemia cell lines; this localization seems to play an important role in ceramide-mediated apoptosis (Sawai et al., 1997). It is possible, therefore, that movement of membrane-bound PKCs to the cytosol may contribute to signal transduction, albeit via mechanisms that are as yet poorly defined.
To further study the relationship between PKC activation and PLD activity, we used the PKC inhibitor GF 109203X (Martiny-Baron et al., 1993). In these studies, GF 109203X, at concentrations that greatly diminished PMA and ATP-mediated activation of PLD, did not decrease epinephrine-promoted accumulation of PEt. From these experiments, along with the studies involving antisense PKC-treated cells, we conclude that PKC activity is not necessary for epinephrine-promoted activation of PLD in MDCK-D1cells. Many investigators have used protocols in which many hours of cell treatment with phorbol esters depletes phorbol ester-activatable PKC isoenzymes. Indeed, we used this experimental approach to implicate a role for PKC in PLD activation (Balboa et al., 1994). Unfortunately, because 18-hr treatment of cells with PMA markedly decreases the number of α1-adrenergic receptors (Yang, M, Buscher R, Taguchi K, Insel PA, and Michel MC. Agonist-induced down-regulation of α1-adrenergic receptors in MDCK cells, submitted for publication), such a protocol is unsuitable for assessment of the role of PKC in mediating α1-adrenergic actions in MDCK-D1 cells.
Stimulation of MDCK-D1 cells with epinephrine leads to a very rapid generation of diacylglycerol, the physiological activator of PKC (Slivka et al., 1988). Such a rapid generation of diacylglycerol could account for the rapid translocation of PKCα and PKCε to the membrane fraction. Phosphoinositide turnover via phospholipase C is not detectable in epinephrine-stimulated MDCK-D1 cells at early time points (<3 min), but increases in phosphorylcholine levels are readily detectable during the first minutes of cell activation with epinephrine (Slivka et al., 1988). Collectively, these data suggest that shortly after receptor occupancy, epinephrine-promoted PC hydrolysis leads to a rapid burst of diacylglycerol formation that, in turn, promotes PKC translocation to the membrane. D609 has been reported to block PC breakdown (Muller-Decker, 1989; Schütze et al., 1992). D609 was able to completely suppress PKCα and PKCεtranslocation to the membrane. Treatment of cells with D609 also dissociated PKCα and PKCε translocation from PLD activation, because the inhibitor did not significantly reduce epinephrine-stimulated PEt accumulation. This result, together with the data obtained with MDCK-D1 cells in which PKCα expression is inhibited and the studies with the PKC inhibitor GF109203X, provides strong evidence that PLD activation by epinephrine is not linked to activation of PKCα or PKCε.
In summary, the current results, along with our previous data (Weiss and Insel, 1991; Llahi and Fain, 1992; Balboa et al., 1994) lend support to a model whereby occupancy of α1-adrenergic receptors on the surface of MDCK-D1 leads to an early accumulation of PC-derived diacylglycerol, which leads in turn to PKCα and PKCε activation. This sequence of events, however, is unrelated to or insufficient to promote activation of PLD activity in epinephrine-stimulated cells. By contrast, in ATP-stimulated or phorbol ester-stimulated cells, PLD activation is downstream of activation of PKCα. Taken together, the data thus indicate that activation of PLD, in a cellular system, can occur independently of activation of PKC (perhaps by a mechanism involving Ca2+ mobilization) and that different types of G protein-linked receptors expressed in a single cell type can activate PLD via both PKCαactivation-dependent and -independent mechanisms.
Acknowledgments
We are grateful to Dr. Jesús Balsinde for useful scientific discussions.
Footnotes
- Received April 2, 1997.
- Accepted October 15, 1997.
-
Send reprint requests to: Dr. Paul Insel, Department of Pharmacology, 0636, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0636.
-
This work was supported by National Institutes of Health Grants GM31487 and HL35018.
-
Work described in this manuscript was presented at the Pharmacology ’97 Meeting held in San Diego, March 1997 (The Pharmacologist 39:63 (1997)).
Abbreviations
- PLD
- phospholipase D
- MDCK
- Madin-Darby canine kidney
- PC
- phosphatidylcholine
- PEt
- phosphatidylethanol
- PKC
- protein kinase C
- PMA
- phorbol-12-myristate-13-acetate
- EGTA
- ethylene glycol bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid
- HEPES
- 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
- The American Society for Pharmacology and Experimental Therapeutics
References
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|